If you have been reading about HGF/c-Met and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
==== 2200–2299 ==== Motor Vehicles (Type Approval for Goods Vehicles) (Great Britain) (Amendment) Regulations 1993 (S.I. 1993/2200) Motor Vehicles (Type Approval) (Great Britain) (Amendment) Regulations 1993 (S.I. 1993/2201) Bananas (Interim Measures) (Revocation) Regulations 1993 (S.I. 1993/2204) Wireless Telegraphy (Television Licence Fees) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/2205) National Health Service (General Dental Services) Amendment Regulations 1993 (S.I. 1993/2209) Dental Vocational Training Authority Regulations 1993 (S.I. 1993/2210) Dental Vocational Training Authority (Establishment and Constitution) and Appeal Body (Specification) Order 1993 (S.I. 1993/2211) Taxes (Interest Rate) (Amendment No. 3) Regulations 1993 (S.I. 1993/2212) Friendly Societies Act 1992 (Commencement No. 6 and Transitional Provisions) Order 1993 (S.I. 1993/2213) Finance Act 1993 (Appointed Day) Order 1993 (S.I. 1993/2214) Finance Act 1993, section 12, (Appointed Day) Order 1993 (S.I. 1993/2215) National Health Service (District Health Authorities) (No.2) Order 1993 (S.I. 1993/2218) National Health Service (Determination of Districts) (No.2) Order 1993 (S.I. 1993/2219) National Health Service (General Dental Services) (Scotland) Amendment Regulations 1993 (S.I. 1993/2224) Parole Board (Scotland) Rules 1993 (S.I. 1993/2225) Transcripts of Criminal Proceedings (Scotland) Order 1993 (S.I. 1993/2226) Prison (Scotland) Amendment Rules 1993 (S.I. 1993/2227) Young Offenders (Scotland) Amendment Rules 1993 (S.I. 1993/2228) Road Traffic Act 1991 (Commencement No.
Amanita virosa is a species of fungus in the class Agaricomycetes. In the UK, it has the recommended English name of destroying angel and is known internationally as the European destroying angel. Basidiocarps (fruit bodies) are agaricoid (mushroom-shaped) and pure white with a ring on the stipe and a sack-like volva at the base. The species occurs in Europe and northern Asia. It was formerly reported from North America, but similar-looking American species like A. bisporigera and A. ocreata are distinct. As the name suggests, the destroying angel is poisonous.
Pauling had formulated a model for the structure of hemoglobin in which atoms were arranged in a helical pattern, and applied this idea to proteins in general. In 1951, based on the structures of amino acids and peptides and the planar nature of the peptide bond, Pauling, Robert Corey and Herman Branson correctly proposed the alpha helix and beta sheet as the primary structural motifs in protein secondary structure. This work exemplified Pauling's ability to think unconventionally; central to the structure was the unorthodox assumption that one turn of the helix may well contain a non-integer number of amino acid residues; for the alpha helix it is 3.7 amino acid residues per turn. Pauling then proposed that deoxyribonucleic acid (DNA) was a triple helix; his model contained several basic mistakes, including a proposal of neutral phosphate groups, an idea that conflicted with the acidity of DNA. Sir Lawrence Bragg had been disappointed that Pauling had won the race to find the alpha helix structure of proteins. Bragg's team had made a fundamental error in making their models of protein by not recognizing the planar nature of the peptide bond. When it was learned at the Cavendish Laboratory that Pauling was working on molecular models of the structure of DNA, James Watson and Francis Crick were allowed to make a molecular model of DNA. They later benefited from unpublished data from Maurice Wilkins and Rosalind Franklin at King's College which showed evidence for a helix and planar base stacking along the helix axis.
=== Affiliations === Dunkin' has a close relationship with the Boston Red Sox and the New England Patriots, making commercials at the start of each team's season for promotions. Dunkin' also sponsors other professional sports teams, including the Dallas Cowboys, New York Yankees, New York Mets, Philadelphia Eagles, and Tampa Bay Rays. In 2001, Dunkin' Donuts purchased the naming rights for the former Providence Civic Center, and renamed it the Dunkin' Donuts Center. In 2022, the arena was renamed the Amica Mutual Pavilion. The center is the home for the NCAA and Big East Providence Friars men's basketball team from Providence College as well as the home for the AHL Providence Bruins hockey team. In reference to the center's long association with local college basketball, it is often known locally as "The Dunk". In January 2014, English football club Liverpool announced a multimillion-pound global partnership with the company. Dunkin' Donuts signed a sponsorship deal with the National Women's Hockey League in December 2015. As part of the multi-year agreement, Dunkin’ Donuts is the official hot, iced and frozen coffee of the NWHL. In 2016, Dunkin' became the official "coffee, doughnut and breakfast sandwich partner" of the National Hockey League.
Sources: en.wikipedia.org
=== On adult health maintenance === Once growth and development are completed, vitamins remain essential nutrients for the healthy maintenance of the cells, tissues, and organs that make up a multicellular organism; they also enable a multicellular life form to efficiently use chemical energy provided by food it eats, and to help process the proteins, carbohydrates, and fats required for cellular respiration.
=== Motorsports career === In 2023, Austin began competing in desert racing with a UTV. He co-owns GFI Racing and drives the No. 316 car in reference to his wrestling catchphrase. Austin won the 2024 Valley Off Road Racing Association championship in the Sportsman UTV class before racing the Mint 400 for the first time in 2025, where he was also the grand marshal. On March 26, 2026, Austin won the Stock Mod Pro Class division Prospector 250, which is a six-hour-long race in the Nevada desert.
=== Psychosis model === Early studies of DET as well as other psychedelics were focused on their presumed psychotomimetic properties. Researchers theorized that abnormal metabolites of endogenous chemicals such as tryptamine, serotonin, and tryptophan could be the explanation for mental disorders such as schizophrenia, or psychosis. DET, along with other synthetic psychedelics, was administered to both patients and healthy volunteers to understand its effects and as a possible biological model for psychosis. With the progression of science and pharmacological understanding, this belief has been dismissed by most researchers.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.